Biosimilar drug marketing of recombinant FSH for the treatment of infertility is another step
in simplifying fertility treatments, making them easier to manage and more accessible to
patients. Taking in mind these arguments ,the study is proposed for determining equivalence
in terms of biological effectiveness of an ovarian stimulation protocol with biosimilar
recombinant FSH stimulation protocol vs. urinary FSH in oocyte donation program.